Passage Bio (NASDAQ:PASG) rose 6.99% on June 23, 2026, as strategic alternatives keep the gene-therapy stock in focus, with shares closing at $6.12.

Key Highlights

  • Rose 6.99%: Passage Bio closed at $6.12 on June 23 after moving $0.40 per share.
  • Catalyst: During the session, strategic alternatives keep the gene-therapy stock in focus.
  • Company: Passage Bio develops gene therapies for neurological diseases and has been reviewing strategic options.
  • Session: The stock finished at $6.12, while the available company record showed a disclosed catalyst for the move.

Passage Bio (NASDAQ:PASG) rose 6.99% on June 23, 2026, closing at $6.12 after a $0.40 per-share move. The session’s advance came as strategic alternatives keep the gene-therapy stock in focus, based on the available company disclosures and trading context.

Speculative gene-therapy sector momentum and continuing investor interest in the company's stated exploration of strategic alternatives helped support the stock. Passage Bio, a clinical-stage gene therapy company with a Penn Medicine collaboration, has been evaluating options including potential partnering or M&A transactions following pipeline restructuring.

Passage Bio develops gene therapies for neurological diseases and has been reviewing strategic options.

No formal transaction announcement was made during the June 23 session.

The transaction or strategic review was the central corporate development behind the session. Such announcements can alter the expected ownership, financing position or operating focus of a listed company, while completion remains governed by the terms and approvals disclosed by the parties.

The stock ended at $6.12, reflecting the market response to the announced corporate action. No additional transaction closing was recorded during the June 23 session beyond the terms described in the available announcement.

For the June 23 close, the defining facts were the 6.99% advance, the $6.12 closing price and the catalyst described above. Any further change in the investment record would require a new filing, financial update, regulatory communication or transaction announcement from the company.